We are proud to announce the 2nd annual RNA Therapeutics USA Conference taking place in Boston on the 23 – 24th October 2024.
As part of our leading portfolio of Drug Discovery and the long-standing RNA Therapeutics Europe conferences, we are delighted to introduce RNA Therapeutics USA.
RNA therapies are leading the way in the field of genetic medicine, with the market expected to reach 1.81 billion USD by 2025, growing at a CAGR of 7.5%. This in large can be attributed to the topical advancements in mRNA vaccines, paving the way for global regulatory successes.
We currently see the RNA Therapeutic field focus on the challenges associated with delivery of RNA molecules extrahepatically, with a particular drive to overcome barriers of delivery to the Central Nervous System. In addition, RNA technologies continue to lead the way in revolutionising immunotherapies and the vaccine landscape, along with exceptional potential to treat a wide variety of chronic, previously undruggable diseases. The 2024 agenda will address these latest challenges along with recent advancements in RNAi and continue to drive innovation in the field of RNA Therapeutics.
Don't miss this opportunity to network with the pharma and biotech community of global experts; the two-day agenda offers you peer-to-peer networking with Directors of novel RNA therapies, CEOs, Senior and expert scientists, Chief Medical Officers, Senior Vice Presidents and many more.
2023 Speakers Included
- Aditya Venkatesh, Senior Principal Scientist, Stoke Therapeutics Inc
- Alfica Sehgal, SVP Head of Discovery & Translation, CAMP4 Therapeutics
- Archit Rastogi, Assistant Director, Preclinical Development , Ionis Pharmaceuticals Inc.
- Chuong Huynh,
Biologist Officially / Vaccine Product Coordination Team Lead
Unofficially, Biomedical Advanced Research & Development Authority
(BARDA)
- Heinrich Haas, Former Vice President Formulation & Drug Delivery, BioNTech
- Ho-Chou Tu, Associate Director, Alnylam Pharmaceuticals
- Jay Sarkar, Researcher and Entrepreneur, Stanford University
- Jimmy Weterings, Senior Director, Technology Innovation, Sirnaomics, Inc
- Martin Akerman, CTO & Co-Founder, Envisagenics
- Michelle Lynn-Hall, Associate Vice President, Genetic Nanomedicine, Eli Lilly
- Ramana Doppalapudi, Vice President Chemistry, Avidity Biosciences Inc.
- Rushit N Lodaya, Expert Scientist, GSK
- Samir Ounzain, CEO, HAYA Therapeutics
- Stefano Zanotti, Senior Director, Head of Neuromuscular Research, Dyne Therapeutics
- Steven Reed, CEO, HDT Bio
- Tamar Grossman, Vice President, Global Head of RNA and Targeted Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson
- Ying Yu, Associate Director, AbbVie
The full agenda is not yet available for this event.
Follow this event to receive an alert when the agenda becomes available.
Venue
Courtyard by Marriott Boston Downtown
275 Tremont St, 02116
Boston, MA, USA
